Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Recommendation of “Buy” from Brokerages

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have earned an average recommendation of “Buy” from the seven brokerages that are covering the stock, MarketBeat reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokers that have issued a report on the stock in the last year is $8.80.

Several brokerages have commented on PYXS. Royal Bank of Canada restated an “outperform” rating and set a $7.00 target price on shares of Pyxis Oncology in a research report on Friday, March 22nd. Jefferies Financial Group restated a “buy” rating and set a $10.00 target price on shares of Pyxis Oncology in a research report on Tuesday, May 7th. Finally, HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Pyxis Oncology in a research report on Thursday, May 16th.

Institutional Investors Weigh In On Pyxis Oncology

Several institutional investors and hedge funds have recently made changes to their positions in PYXS. Acadian Asset Management LLC purchased a new stake in shares of Pyxis Oncology in the 3rd quarter worth about $26,000. Schulhoff & Co. Inc. purchased a new stake in shares of Pyxis Oncology in the 3rd quarter worth about $44,000. SG Americas Securities LLC purchased a new stake in shares of Pyxis Oncology in the 1st quarter worth about $59,000. Cetera Advisors LLC purchased a new stake in shares of Pyxis Oncology in the 1st quarter worth about $100,000. Finally, Radcliffe Capital Management L.P. purchased a new stake in shares of Pyxis Oncology in the 3rd quarter worth about $106,000. 39.09% of the stock is currently owned by hedge funds and other institutional investors.

Pyxis Oncology Stock Performance

Shares of PYXS opened at $3.38 on Friday. The stock has a market capitalization of $199.05 million, a P/E ratio of -2.49 and a beta of 1.33. The company’s fifty day moving average is $4.10 and its two-hundred day moving average is $3.88. Pyxis Oncology has a 1 year low of $1.35 and a 1 year high of $6.85.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings data on Saturday, May 11th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.19. The firm had revenue of $16.15 million during the quarter, compared to analyst estimates of $4.25 million. Sell-side analysts predict that Pyxis Oncology will post -1.09 EPS for the current year.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.